Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US

CONCLUSION: This study documented the real-world change in CLL treatment landscape and the substantial economic burden of patients with CLL/SLL. Specifically, targeted therapies were increasingly used as 1L treatments and they were part of more than half of 1L regimens in recent years (2018-2021).PMID:38280190 | DOI:10.1093/oncolo/oyad324

Source: The Oncologist - January 27, 2024 Category: Cancer & Oncology Authors: Xiaoqin Yang Enrico Zanardo Dominique Lejeune Enrico De Nigris Eric Sarpong Mohammed Farooqui Fran çois Laliberté Source Type: research